BOSTON– Biotechnology companies Leveragen and Propeller Bio have announced a strategic collaboration aimed at accelerating the development of next-generation antibody and protein-based therapeutics.
Under the partnership, newly launched Propeller Bio will invest in Leveragen’s platform technologies and gain access to the Boston-based firm’s proprietary suite of antibody mouse models. This includes the Singularity Sapiens Mouse, a fully human single-domain antibody discovery platform designed to generate in vivo matured human VH-only antibodies with broad diversity and therapeutic potential.
The Singularity Sapiens Mouse is engineered to elicit strong immune responses across a wide range of antigens and supports various therapeutic formats, such as bispecifics, antibody-drug conjugates, CAR-T therapies, and mRNA-encoded antibodies.
“We’re excited to collaborate with Dr. David Shen and the team at Propeller Bio,” said Weisheng Chen, Ph.D., Founder and CEO of Leveragen. “David has a remarkable track record of bringing innovative biomedicines to patients in need. We believe Propeller Bio is well positioned to lead the next wave of therapeutic breakthroughs, and we’re proud to support their work with our cutting-edge antibody discovery platforms.”
Propeller Bio is led by Founder and CEO David W. Shen, Ph.D., a veteran in antibody and protein therapeutics with prior leadership roles at Amgen, Merck, Teva, and NGM Bio. Shen also founded Proteologix, a bispecific antibody developer acquired by Johnson & Johnson in 2024 for $850 million upfront.
“Leveragen’s Singularity Sapiens Mouse is a differentiated platform for antibody discovery,” said Shen. “It provides a unique option for high-quality, in vivo matured human VH domains with impressive diversity and developability. This platform presents a compelling alternative to camelid immunization or synthetic libraries, offering speed, flexibility, and translational relevance.”
The partnership further establishes Leveragen as a key discovery partner for biotech companies focused on biologics innovation.
